IP Library Patent Application 14941337
Patent Application
App. No. 14/941,337

Methods for Determining The Risk of Prenatal Complications

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/941,337
Abstract

The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.

Claims (25)

1 . A method for determining the risk of pre-eclampsia in a pregnant individual, comprising:

determining the amount of one or more biochemical markers selected from placental growth factor (PlGF) and pregnancy-associated plasma protein A (PAPP-A) in one or more blood samples from the individual;

determining the blood pressure of the individual; and

determining the risk of pre-eclampsia using the amount of each of the selected one or more biochemical markers and the blood pressure of the individual,

wherein determining the risk comprises determining a likelihood ratio for blood pressure and calculating a final risk based on the individual's prior risk of developing pre-eclampsia and a set of likelihood ratios based on the amounts of the one or more biochemical markers and the blood pressure.

2 . The method of claim 1 , further comprising determining uterine artery pulsatility index (PI) of the individual; and determining the risk of pre-eclampsia using the amount of each of the selected one or more biochemical markers and the blood pressure of the individual, and the PI.

3 . The method of claim 1 , wherein the pre-eclampsia is early pre-eclampsia.

4 . The method of claim 1 , wherein the one or more biochemical markers is PlGF.

5 . The method of claim 1 , wherein the one or more biochemical markers is PAPP-A.

6 . The method of claim 1 , wherein the one or more biochemical markers are PlGF and PAPP-A.

7 . The method of claim 1 , further comprising determining the amount of placental protein 13 (PP13) and determining the risk of pre-eclampsia using the amount of each of the selected one or more biochemical markers, the blood pressure of the individual and amount of PP13.

8 . The method of claim 1 , wherein the blood pressure is mean arterial blood pressure.

9 - 10 . (canceled)

11 . The method of claim 1 , wherein multivariate Gaussian analysis is performed to determine the likelihood ratios.

12 . The method of claim 1 , further comprising using likelihood ratios for one or more maternal history parameters selected from race, smoking, parity, BMI, hypertension, previous pre-eclampsia, and mother/sister with previous pre-eclampsia.

13 . The method of claim 1 , wherein the method for determining the risk of pre-eclampsia in an individual has a detection rate of at least about 65% and a false positive rate of about 10%.

14 . The method of claim 1 , wherein the method for determining the risk of pre-eclampsia in an individual has a detection rate of at least about 75% and a false positive rate of about 10%.

15 . The method of claim 1 , wherein the method for determining the risk of pre-eclampsia in an individual has a detection rate of at least about 90% and a false positive rate of about 10%.

16 . The method of claim 1 , wherein the method for determining the risk of pre-eclampsia in an individual has a detection rate of at least about 95% and a false positive rate of about 10%.

17 . (canceled)

18 . An apparatus for determining the risk of pre-eclampsia in a pregnant individual, comprising:

a data input means for inputting the amounts of one or more biochemical markers selected from placental growth factor (PlGF) and pregnancy-associated plasma protein A (PAPP-A) in one or more blood samples from the individual, and the blood pressure of the individual; and

a calculation means for determining the risk of developing pre-eclampsia using the input amounts of the biochemical markers and the blood pressure,

wherein determining the risk comprises determining a likelihood ratio for blood pressure and calculating a final risk based on the individual's prior risk of developing pre-eclampsia and a set of likelihood ratios based on the amounts of the one or more biochemical markers and the blood pressure.

19 . (canceled)

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2019
From: THE FETAL MEDICINE FOUNDATION
To: WALLAC OY
Reel/Frame 051332/0883 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2016
From: PERKINELMER HEALTH SCIENCES, INC.
To: WALLAC OY
Reel/Frame 039509/0937 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2015
From: AHOLA, TARJA
To: PERKINELMER HEALTH SCIENCES, INC.
Reel/Frame 037067/0232 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2015
From: CUCKLE, HOWARD
To: WALLAC OY
Reel/Frame 037067/0251 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2015
From: NICOLAIDES, KYPROS; POON, LEONA
To: THE FETAL MEDICINE FOUNDATION
Reel/Frame 037067/0279 →